In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IN VIVO Execs On The Move, June 2014

Executive Summary

Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.

You may also be interested in...



WHO Drafting Regulatory Convergence White Paper On Cell And Gene Therapies, US FDA's Marks Says

Regulators in high-income countries have a responsibility to help health authorities in low- and medium- income countries develop regulatory frameworks for cell and gene therapy products to ensure these treatments are available to all, asserts the US FDA’s biologics center’s director.

Top Democrats: Trump Admin’s COVID-19 Insurance Guidance Poses ‘Serious Threat’

Democratic lawmakers argue the Trump administration’s interpretation of how COVID-19 testing is covered by private insurers runs contrary to the Families First Act and CARES Act. They want the administration to update a FAQ sheet that eliminates certain prerequisites that would qualify patients to be reimbursed for the tests.

Exec Chat: Boston Scientific’s Angelo De Rosa Forsees Digital Transformation In The COVID-19 Era

Angelo De Rosa, vice president of Boston Scientific's cardiac rhythm management business in Europe, the Middle East and Asia, talked to Medtech Insight about the opportunities to accelerate digital transformation in health care during the COVID-19 crisis.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel